ReviewChildren (Basel, Switzerland)2020
An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics.
Review in Children (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 61 citations in OpenAlex.
- Slaughter blood-derived bioactive peptides: structure-function relationships, species-specific bioactivities, gastrointestinal stability, and sustainable applications in food systems.Food science of animal resources · 2026Review
- Therapeutic peptides and proteins: Status and developments in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Engineering Antimicrobial Peptides via Motif Assembly for Combating Multidrug-Resistant Pathogens.Journal of medicinal chemistry · 2026Article
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Strategic Approaches for Overcoming Peptide and Protein Drug Limitations.The protein journal · 2026Review
- Limited willingness to switch from intravenous to subcutaneous treatment in paediatric inflammatory bowel disease.BMJ paediatrics open · 2026Article
- Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms.Biomedicines · 2025Review
- Recent advances in the therapeutics and modes of action of a range of agents used to treat ulcerative colitis and related inflammatory conditions.Inflammopharmacology · 2025Review
- Influence of Peptide Conjugation Sites on Lunatin-Alumina Nanoparticles: Implications for Membrane Interaction and Antimicrobial Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Advances in the Oral Delivery of Protein and Peptide Drugs.Pharmaceutics · 2025Article
- Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview.International journal of molecular sciences · 2024Review
- Review
- Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: Application to bevacizumab.Drug delivery and translational research · 2024Article
- Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs.Pharmaceutics · 2023Review
- Lunasin as a Promising Plant-Derived Peptide for Cancer Therapy.International journal of molecular sciences · 2022Review
- Citric Acid: A Multifunctional Pharmaceutical Excipient.Pharmaceutics · 2022Review
- Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery.Pharmaceutics · 2021Article
- Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy.Viruses · 2021Review
- Challenges and opportunities in delivering oral peptides and proteins.Expert opinion on drug deliveryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While each route of therapeutic drug delivery has its own advantages and limitations, oral delivery is often favored because it offers convenient painless administration, sustained delivery, prolonged shelf life, and often lower manufacturing cost. Its limitations include mucus and epithelial cell barriers in the gastrointestinal (GI) tract that can block access of larger molecules including Therapeutic protein or peptide-based drugs (TPPs), resulting in reduced bioavailability. This review describes these barriers and discusses different strategies used to modify TPPs to enhance their oral bioavailability and/or to increase their absorption. Some seek to stabilize the TTPs to prevent their degradation by proteolytic enzymes in the GI tract by administering them together with protease inhibitors, while others modify TPPs with mucoadhesive polymers like polyethylene glycol (PEG) to allow them to interact with the mucus layer, thereby delaying their clearance. The further barrier provided by the epithelial cell membrane can be overcome by the addition of a cell-penetrating peptide (CPP) and the use of a carrier molecule such as a liposome, microsphere, or nanosphere to transport the TPP-CPP chimera. Enteric coatings have also been used to help TPPs reach the small intestine. Key efficacious TPP formulations that have been approved for clinical use will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.